Native Bacterial And Viral Antigens

Native antigens are extracted in their natural form from the respective sources. As they undergo usual modifications in vivo, upon isolation, they exhibit close resemblance withthe complex 3-dimensional structure they exhibit in the host. In the case of protein antigens, these modifications may include post-translational alterations such as cleavage of precursor proteins, formation of disulphide bonds, and addition of low molecular weight groups through processes such as glycosylation or phosphorylation.

Antigens are the biomolecules that are capable of triggering immune response in host body through the activation of lymphocytes. Bacterial antigens are used in the development of various types of antibodies in research laboratories for the improvement of immune systems. Moreover, bacterial antigens are also widely used in immunodiagnostic assays such as ELISA.

Download PDF Brochure Here

Panning of native antigen libraries have led to development of potent neutralization antibodies against various bacterial and viral infections. The native antigens are extracted in their natural form from a corresponding source. There is high demand for a large number of native antigens, especially in in vitro diagnostics and vaccine research. According to various scientific studies, recombinant antigens exhibit solubility and aggregation issues. Further, the association of recombinant antigens with non-protein entities is also different and sometimes lacking in terms of performance as compared to native antigens.

With the recent outbreak of COVID-19, companies are developing commercial SARS-CoV-2 antigens to support the vaccine formulation, and research and development to strengthen the disease diagnosis and therapy. In February 2020, the Native Antigen Company became the first company to commercially provide the novel coronavirus antigens, using the company’s proprietary VirtuE (HEK293) expression system. Thus, the rising use of native antigens, effectively supporting the diagnostics and therapeutics of various medical conditions, boosts the growth of the native bacterial antigen and antibody market.

The native bacterial and viral antigens market, based on product type, is segmented into chlamydia antigens, adenovirus antigens, borrelia antigens, clostridium antigens, chikungunya virus antigens, and dengue virus antigens. The chlamydia antigens segment held the largest share of the market in 2019, and the market for the same is anticipated to grow at the highest CAGR during the forecast period. Growth of the market for this segment is attributed to easy availability of these antigens, with majority of the market players commercially offering these antigens in the native forms. Further, the use of chlamydia antigens in research institutes and laboratories for the development of vaccines and in vitro diagnostics (IVD) tests is further expected to propel the growth of the market for this segment.

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios; these strategies help them meet the growing consumer demand. Collaboration is one of the major strategies adopted by the companies operating in the native bacterial and viral antigens market to enlarge customer base worldwide, which also permits them to maintain their brand name globally.

Native Bacterial and Viral Antigens

• Chlamydia Antigens 

• Adenovirus Antigens
• Borrelia Antigens
• Chikungunya Virus Antigens
• Clostridium Antigens
• Dengue Virus Antigens